TICKERNERD
Menu
IMAIMAHealthcare · Biotechnology

IMA Stock Forecast: ImageneBio, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$4.70
+2.17% on the day

The 4 Wall Street analysts covering ImageneBio, Inc. hold a median 12-month price target of $24 — +410.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$52.2M
Ticker Nerd rank
26 / 100
Median analyst target
$24
Analysts covering
4
Revenue$0.0−100.0% y/y
Operating income−$11.8M
Net income−$10.2M
Free cash flow−$9.1M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.3%
1M
−3.1%
YTD
−31.9%
1Y
−45.3%
From 52W high
−46.5%
From 52W low
+3.3%
$4.55
$8.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImageneBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
81
Volatility
76
Revisions
64
Quality
55
Issuance
38
Accruals
28
Growth
25
Value
8
Momentum
4

Size (81): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26IMAHigh $28Median $24Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy0 Hold1 Sell
Low $2Median $24High $28

The green dot is the last close — the median target sits +410.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026HC Wainwright & Co.InitiatesBuy$28
11 May 2026WedbushReiteratesUnderperform$2.00
11 May 2026WedbushReiteratesUnderperform—
25 Nov 2025WedbushAssumesUnderperform$2.00
24 Oct 2025Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, ImageneBio, Inc. returned −45.3% against +16.2% for the S&P 500, dividends included.

IMA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26IMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

ImageneBio, Inc. (IMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
65.3×

Cheaper than 5% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
1.4×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−6056.4%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−82.7%

Higher than 15% of US stocks

Return on assets
−43.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ImageneBio, Inc. (IMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ImageneBio, Inc. has a market value of $52.2M and an enterprise value of −$82.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$52.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$52.6M.

  • Shares outstanding: 11.3M.

  • Trailing P/E: −0.5×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ImageneBio, Inc. employs 18 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

IMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMAImageneBio, Inc.$52.2M
26
EXOZeXoZymes, Inc.$53.6M
13
HYPDHyperion DeFi, Inc.$56.5M
40
EDSAEdesa Biotech, Inc.$52.2M
50
KLRSKalaris Therapeutics, Inc.$56.6M
18
CELUCelularity, Inc.$51.9M
30
INMBINmune Bio, Inc.$51.3M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImageneBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMA news & analysis

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

ImageneBio's Compensation Committee granted inducement awards on September 30, 2026, consisting of 90,775 restricted stock units and 32,725 non-qualified stock options to three newly hired non-executive employees. The awards were granted as inducements material to the new employees joining the company, under Nasdaq Listing Rule 5635(c)(4) and the company's 2025 Equity Inducement Plan.

Why it matters — A watcher would care because these inducement grants signal new non-executive hires retained with equity compensation, potentially adding to share dilution and reflecting the company's hiring activity.

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

GlobeNewsWire · 8 Sept 2026neutral

ImageneBio, Inc. announced that CEO Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and that management will hold one-on-one meetings at the event.

Why it matters — An IMA watcher would care because the conference participation gives investors and analysts opportunities to hear directly from the CEO and management about the company.

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

ImageneBio announced that on August 14, 2026, its Compensation Committee granted inducement awards to three newly hired non-executive employees, comprising 79,000 restricted stock units and 56,525 non-qualified stock options, under Nasdaq Listing Rule 5635(c)(4). The company also granted inducement awards of 65,000 RSUs and 56,000 NSOs to Chief Financial Officer Yanina Grant-Huerta, who additionally received 39,000 RSUs under the 2025 Equity Incentive Plan.

Why it matters — The inducement grants signal new executive and employee hiring and equity incentives tied to the company's 2025 equity plans, which IMA watchers may track for compensation and dilution effects.

ImageneBio Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 5 Aug 2026neutral

ImageneBio reported its financial results for the second quarter ended June 30, 2026, and provided a company update highlighting its OX40-targeting candidate Olevaprubart (IMG-007).

Why it matters — The update provides the first look at the company's financial position and progress on Olevaprubart, a potential first-in-class OX40 antagonist that is ImageneBio's lead pipeline candidate.

FAQ

Frequently asked questions about IMA stock

What is the IMA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImageneBio, Inc. have a median 12-month price target of $24, with estimates ranging from $2 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMA stock a buy right now?

Of the 4 analysts covering ImageneBio, Inc., 3 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ImageneBio, Inc. 26 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMA?

As at 3 Oct 2026, ImageneBio, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).

Will IMA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +410.6% from the last close, and Ticker Nerd's factor model ranks ImageneBio, Inc. 26 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMA stock forecast for 2030?

No analyst covering ImageneBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $28 over the next 12 months.

How has IMA stock performed over the past year?

ImageneBio, Inc. returned -45.3% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImageneBio, Inc. do?

ImageneBio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases.

What is the latest news on IMA?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". ImageneBio's Compensation Committee granted inducement awards on September 30, 2026, consisting of 90,775 restricted stock units and 32,725 non-qualified stock options to three newly hired non-executive employees. The awards were granted as inducements material to the new employees joining the company, under Nasdaq Listing Rule 5635(c)(4) and the company's 2025 Equity Inducement Plan.

Company

About ImageneBio, Inc.

ImageneBio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases. Its lead program, IMG-007, is a non-depleting anti-OX40 monoclonal antibody designed to modulate OX40 receptor signaling on activated T cells, with development centered on conditions such as atopic dermatitis and alopecia areata. The company also explores broader applications in immune-mediated disorders, reflecting a research pipeline built around differentiated treatment approaches for chronic inflammatory disease. Based in San Diego, California, ImageneBio Inc. plays a specialized role in the biotechnology market by advancing targeted antibody-based therapies aimed at improving disease control in areas with significant unmet medical need.

CEO Dr. Kristin Yarema Ph.D. · 18 employees · United States · https://www.inmagenebio.com